Vaccine Info

Sputnik M Vaccine

Authored by
Staff
Last reviewed
December 6, 2021
Fact checked by
Robert Carlson, MD
Share

Sputnik M Vaccine Description

The Sputnik M vaccine (Gam-COVID-vac M) is a recombinant human adenoviral-based, two-part vaccine against the SARS-CoV-2 betacoronavirus that stimulates an immune response. In addition, Sputnik M is indicated to build immunity to SARS-CoV-2, which causes COVID-19 in children and adolescents.

The vaccine consists of two components: Component I includes a recombinant adenoviral vector based on human adenovirus serotype 26 carrying the gene for the S-protein of the SARS-CoV-2 virus, and component II includes a vector based on human adenovirus serotype 5 carrying the protein S gene of the SARS-CoV-2 virus. The Sputnik M vaccine is produced with the HEK293 cell line and is produced as a liquid formulation containing 10¹¹ vp per 0·5 mL/dose.

The Russian state institute Gamaleya National Research Centre of Epidemiology and Microbiology developed the Sputnik V vaccine. The technological platform of adenovirus-based vectors makes it easier and faster to create new vaccines by modifying the initial carrier vector with genetic material from new emerging viruses that help develop new vaccines relatively quickly. Moreover, such vaccines provoke a strong response from the human immune system.

The unique substance of the Sputnik V and method of using it has patent protection in Russia, obtained by Gamaleya.

The Russian Direct Investment Fund is a sovereign investment fund of the Russian Federation. The Foundation was established in 2011 at the initiative of the President and Prime Minister of the Russian Federation.

Sputnik M Vaccine Indication

The efficacy of Sputnik V against COVID-19 was reported at 91.6%. The figure is based on data analysis on 19,866 volunteers who received the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases. In addition, Sputnik V's efficacy was validated by internationally peer-reviewed data published in The Lancet on February 2, 2021.

The Ulema Council confirmed in March 2021' faith does not forbid Russian Muslims from getting vaccinated with Sputnik V, after considering the Covid-19 vaccine for Sharia compliance.'

Sputnik M Vaccine Dosage

Sputnik M vaccine consists of the two components of Sputnik V but is being tested administering the vaccine as 1/5 the dosage. For intramuscular injection.

Sputnik M Vaccine Availability

Media reports indicate the Sputnik M vaccine availability in Russia and India could be at the end of 2021

Sputnik M Vaccine Effectiveness Against SARS-CoV-2 Virus Variants

Data from NITsEM named after N.F. Gamaleas obtained on the basis of a single vaccination of 28 thousand people with Sputnik Light showed that, when used alone, the effectiveness of the vaccine is 70% against the Delta variant within three months after vaccination.

Sputnik V Vaccine

The Sputnik V vaccine (Gam-COVID-Vac) is an adenoviral-based, two-part vaccine against the SARS-CoV-2 coronavirus Registered in August 2020.

Sputnik Light Vaccine

Sputnik Light Vaccine is a single dose of the recombinant human adenovirus 26 serotype (rAd26). 

Sputnik M Vaccine News

December 6, 2021 - Sputnik M's registration is pending in India's to become the first overseas registered vaccine for adolescents aged 12-17.

November 24, 2021 - TASS reported the Deputy Director-General of the Gamaleya Research Institute of Epidemiology and Microbiology Denis Logunov confirmed at a press conference today 'The use of the Sputnik vaccine on children was authorized today, the vaccine was approved.'

November 24, 2021 - Deputy Prime Minister Tatiana Golikova informed the media the Sputnik M vaccine would be registered today.

November 22, 2021 - Only mild side effects have been linked to the Sputnik M vaccine tested in teens. "These clinical tests demonstrated that teenagers aged from 12 to 17 react well in terms of developing protective antibodies after inoculation, much better than the adult population reacts to Sputnik V in its classical variant," said Alexander Gintsburg, director of the Gamaleya Center.

November 19, 2021 - Sputnik M has entered Phase 3 clinical trials. Sputnik M will be the COVID-19 vaccine for 12-17 years old.

July 8, 2021 - A double-blind, placebo-controlled phase 2 study launched with an open dose selection period for safety assessment, tolerance, and immunogenicity of the drug "GamKOVID-Vac M, a combined vector vaccine for prevention of coronavirus infection caused by the virus SARS-CoV-2" in adolescents

Sputnik M Vaccine Clinical Trials

Phase 1 and 2 clinical trials of the Sputnik V vaccine were completed on August 1, 2020.

ClinicalTrials.gov Identifier: NCT04954092: Sputnik M is being tested in 12 - 17-year-old teens. The trials are being conducted by the Gamaleya National Research Center for Epidemiology and Microbiology. The trials are taking place in 10 outpatient clinics and two children's hospitals.  About four hundred teens have received the first component of Sputnik M, and early results show it's safe and effective.

Clinical Trials

No clinical trials found